Wolowacz SE, Roskell N, Kelly S, Maciver FM, Brand CS. Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in the UK. Pharmacoeconomics. 2007 Oct 1;25(10):863-79.
Javitt JC, Wolowacz SE, Roskell NS, Maciver F, Pleil A, Zlateva G. Balancing visual acuity benefits with systemic adverse effects in anti-VEGF therapy. Poster presented at the ARVO 9th Annual Meeting; May 2007; May 2007. Fort Lauderdale, FL.
Wolowacz SE. Economic analysis of macugen for age-related macular degeneration. Poster presented at the Royal College of Surgeons; February 2, 2007. London, England.
Wolowacz SE, Khan SB. The New National Institute of Health and Clinical Excellence (NICE) Single Technology Appraisal (STA) process: experience from the first completed appraisals. Ispor Connections. 2007;13(2):12-5.
McCrink L, Allen RP, Wolowacz SE, Sherrill B, Connolly M, Kirsch J. Predictors of health-related quality of life in sufferers with restless legs syndrome: a multi-national study. Sleep Med. 2007 Jan 1;8(1):73-83.